IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizoti

Go back to IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizoti
(NASDAQ: IDYA) Delayed: 28.98 +0.14 (0.49%)
Previous Close $28.84    52 Week High
Open $29.01    52 Week Low
Day High $29.76    P/E N/A 
Day Low $28.90    EPS
Volume 617,365